Rozhivanov R V, Chernova M O, Ioutsi V A, Mel'nichenko G A, Shestakova M V, Mokrysheva N G
Endocrinology Research Centre.
Probl Endokrinol (Mosk). 2022 Jun 16;68(3):113-120. doi: 10.14341/probl13129.
BACKGROUND: Type 2 diabetes mellitus (DM2) in men is associated with a high incidence of hypogonadism. Testosterone is a steroid hormone and one of the final metabolites of steroidogenesis, which causes interest in assessing the content of key steroid hormones, their precursors and metabolites in hypogonadal and eugonadal men with T2DM.
AIMS: Assessment of the features of steroidogenesis in men with hypogonadism in T2DM using tandem mass spectrometry.
MATERIALS AND METHODS: A full-design, cross-sectional, screening, single-center, non-interventional study included men with T2DM, who were he was treated in Endocrinology Research Centre, Moscow. The study was conducted from October 2021 to January 2022. Medical history assessment, physical examination with determination of body mass index (BMI), measurement of key steroid hormones, their precursors and metabolites by isotope dilution liquid chromatography/tandem mass spectrometry, glycated hemoglobin (HbA1c) were performed. The groups were compared using the Mann-Whitney U-test for quantitative indicators and χ² with Yates’ correction for qualitative ones. Correlation analysis was performed by the Spearman correlation method. When determining the criterion of statistical significance, the Bonferroni correction was applied.
RESULTS: Patients with hypogonadism had statistically significantly more pronounced obesity compared with eugonadal men. In a comparative analysis of patients, depending on the presence of hypogonadism, there were statistically significantly lower levels of androgen precursors 17-hydroxypregnenolone and 17-hydroxyprogesterone in hypogonadal men. At the same time, a positive statistically significant correlation was found between total testosterone and 17-hydroxyprogesterone. In addition, 17-hydroxyprogesterone, although to a lesser extent, but positively correlated with other androgens - androstenedione (r=0,328; p<0,001) and dehydroepiandrosterone (r=0,183; p=0,004). >< 0,001) and dehydroepiandrosterone (r=0,183; p=0,004).
CONCLUSIONS: In this investigation the prevalence of male hypogonadism in type 2 diabetes, determined by high-precision tandem mass spectrometry, was 69,5%. There was no effect of the disease on the mineralocorticoid and glucocorticoid links of adrenal steroidogenesis. Hypogonadism was associated with decreased levels of a number of testosterone precursors. The most significant of them was 17-hydroxyprogesterone, which can be considered as a marker of testicular steroidogenesis.
男性2型糖尿病(DM2)与性腺功能减退的高发病率相关。睾酮是一种类固醇激素,也是类固醇生成的最终代谢产物之一,这引发了人们对评估2型糖尿病性腺功能减退和性腺功能正常男性体内关键类固醇激素及其前体和代谢产物含量的兴趣。
使用串联质谱法评估2型糖尿病中性腺功能减退男性的类固醇生成特征。
一项全设计、横断面、筛查、单中心、非干预性研究纳入了在莫斯科内分泌研究中心接受治疗的2型糖尿病男性患者。研究于2021年10月至2022年1月进行。进行了病史评估、测定体重指数(BMI)的体格检查、通过同位素稀释液相色谱/串联质谱法测量关键类固醇激素及其前体和代谢产物、糖化血红蛋白(HbA1c)。使用Mann-Whitney U检验比较定量指标组,使用经Yates校正的χ²检验比较定性指标组。采用Spearman相关方法进行相关性分析。在确定统计学显著性标准时,应用了Bonferroni校正。
与性腺功能正常的男性相比,性腺功能减退的患者肥胖更为明显,具有统计学意义。在对患者的比较分析中,根据性腺功能减退的存在情况,性腺功能减退男性体内雄激素前体17-羟孕烯醇酮和17-羟孕酮的水平在统计学上显著较低。同时,总睾酮与17-羟孕酮之间存在统计学显著正相关。此外,17-羟孕酮虽然程度较轻,但与其他雄激素——雄烯二酮(r = 0.328;p < 0.001)和脱氢表雄酮(r = 0.183;p = 0.004)呈正相关。
在本研究中,通过高精度串联质谱法确定的2型糖尿病男性性腺功能减退患病率为69.5%。该疾病对肾上腺类固醇生成的盐皮质激素和糖皮质激素环节没有影响。性腺功能减退与多种睾酮前体水平降低有关。其中最显著的是17-羟孕酮,它可被视为睾丸类固醇生成的标志物。